香京julia种子在线播放

The 2020 Global Cancer Statistics report shows that female breast cancer is the most common cancer worldwide, with the highest number of new cases annually (approximately 11.7% of all new cases in both men and women), having overtaken lung cancer (11.4%) (1). There are four main subtypes of breast cancer, approximately 75% of them are positive for ER and/or PR (2). The luminal A (ER and PR positive, HER2 negative, low Ki67) subtype accounts for approximately 40% of all cases; it is characterized by low invasiveness, a low recurrence rate, a high survival rate, and the best response to hormonal therapy (3). In turn, the luminal B (ER and PR positive, HER2 positive or HER2 negative, with high Ki67) subtype is responsible for 10–20% of all cancer cases, has a higher relapse rate, proliferative index, and lower recurrence survival (4–6). HER2 positive (non-luminal) were defined as HER2 overexpression or amplification, ER and PR absence, and survival rate significantly improvement with targeted therapy (7). Triple‐negative breast tumors (TNBC) are defined as ER, PR, and HER2 negative. TNBC which makes up approximately 15% of all breast tumors and have a high risk of distant relapse in the first 3 to 5 years following diagnosis (8, 9).

With advances in early diagnosis and comprehensive treatment, the prognosis for patients with breast cancer has improved; however, the incidence of metastasis is also increasing (10). It has been reported that 20%–30% of patients with breast cancer can develop metastases after diagnosis and treatment of the primary tumor, with metastases being the cause of approximately 90% of deaths (11). Breast cancer shows a tendency to metastasize to a variety of organs, including bone, lung, liver, and brain, which is termed metastatic heterogeneity. Bone metastases account for approximately 75% of metastases (12), with an overall 5-year survival rate of 22.8% (13). Lung is the second most common site of breast cancer metastasis (14), with an overall 5-year survival rate of 16.8%. The liver is second only to lung as a metastasis site, but survival is poor relative to local, bone, and lung recurrences, with an expected 5-year overall survival rate of 8.5% (15). Brain accounts for approximately 15%–30% of metastatic sites in patients with metastatic breast cancer, limiting quality of life and a very short life expectancy (16–18).

The priority of metastasis varies from organ to organ, resulting in differences in prognosis and treatment response. A widely accepted model of metastasis is the “seed and soil” hypothesis proposed by Paget (19), which initially revealed that successful colonization of second organs depends on the intrinsic properties of the tumor cells and the compatibility and support of the microenvironment.

Bacteroides fragilis is a common colonic colonizing enterobacterium (138) whose virulence is attributed to a 20 kDa zinc metalloprotease toxin known as B. fragilis toxin (BFT) (139). With reference to the effect of enterotoxigenic B. fragilis (ETBF) intestinal or ductal colonization on breast cancer progression in the mammary intraductal model, Parida S et al. (140) colonized BALB/c mice via the teats with ETBF or a non-toxic mutant B. fragilis (086Mut) that does not secrete BFT. The presence of BFT was found to be detected in the mammary glands of ETBF-carrying mice compared to controls, with a 3.9-fold higher tumor volume than 086Mut controls, enhanced lung and liver metastases, and more proliferative tumors forming in the ETBF group, exhibiting a mesenchymal phenotype. Moreover, trichrome staining showing significantly higher stromal infiltration, demonstrating that ETBF intestinal or ductal colonization was associated with breast cancer progression and distant metastasis. Furthermore, significant differences in breast tissue structure were found in the ETBF group compared with the 086Mut control group (140), including extensive local inflammation and tissue fibrosis, Ki-67 and proliferating cell nuclear antigen staining showed increased epithelial cell proliferation, CD3 staining showed increased T-cell infiltration, and significantly altered expression of pan-keratin, all indicating that BFT was associated with a significant increase in oncogenic cell activity and growth rate. The study also found that RNA-seq analysis of secondary tumors arising from breast cancer cells treated with BFT showed enrichment of the β-catenin pathway. The expression of several Notch-responsive genes was enriched in breast cancer cells suggesting that BFT also triggered activation of the Notch1 pathway. The results advance our understanding of the molecular mechanisms associated with ETBF/BFT and breast cancer progression (140), and point to a hypothesis that dysbiosis or disruption of the gut flora might be associated with breast cancer metastasis and progression, and that inhibition of manipulable key molecules or pathways could potentially reduce the impact of ETBF infection on breast cancer.

In looking at whether BFT affects the tumorigenicity of breast cancer cells, the team found that, compared with cells from the control group, BFT-pretreated MCF-7 and MCF-10A cell groups showed greater invasion and migration, with local tumor expansion and the formation of multifocal tumors resembling local metastases (140).However, it was not clear whether ETBF spread from within the gut to the breast or whether gut-infected mice acquired the mammary gland infection through environmental factors. Data from RNA-seq analysis of secondary tumors with limited in vivo formation showed higher expression of genes associated with migration, homing, and metastasis in the BFT pre-treatment group, suggesting that BFT production by ETBF intestinal colonization might be associated with the initiation of breast cancer metastasis; and breast cells exposed to BFT showed dramatic changes supporting cell motility, embryonic pluripotency pathways, expression of metastatic genes, and molecular mechanisms. However, it cannot be demonstrated that ETBF can be the sole driver directly triggering the transformation of human breast cells into tumor cells or interacting with other microbiota to show oncogenic activity.

To assess the effect of pre-established dysbiosis on the metastasis of hormone receptor–positive (HR+) breast cancer in a more aggressive and metastatic tumor model, Parida S et al. (141) evaluated tumor spread to the lung and axillary lymph nodes in a highly metastatic MMTV-PyMT mouse model with reference to the poorly metastatic HR+ mouse breast cancer cell line BRPKp110. The results were similar to those observed in the BRPKp110 cell line: where the spread of tumor cells to the lung was significantly increased after commensal dysregulated of the intestinal flora due to antibiotic treatment, independent of tumor volume. Moreover, the tumors progressed with the same kinetics regardless of the symbiotic dysregulation status in the experimental mice, suggesting that symbiotic dysregulation has a significant and sustained effect on HR+ breast cancer dissemination and that the enhanced ability of cancer cells to spread in symbiotically dysregulated mice is independent of tumor growth kinetics. To confirm the impact of the flora-dysregulation-driven host-intrinsic differences in inducing propagation in a mammary tumor model, they tested the symbiotic dysregulation using the L-Stop-L-KRasG12Dp53flx/flxL-Stop-L-Myristoylated p110α-GFP+ induced mouse model of breast cancer (141), and found that consistent with that observed in the homozygous model, the lungs of mice with dysbiosis of the intestinal flora showed a higher frequency of disseminated tumor cells. No significant increase in GFP+ tumor cells was observed in the distal lymph nodes. Those results confirmed that dysbiosis is independent of primary tumor growth and is associated with enhanced tumor cell dissemination; they also suggest that the tumor dissemination enhancement is the result of host dysbiosis rather than of intrinsic differences in tumor aggressiveness. Macrophages in the mammary gland may promote the metastasis of mammary tumors in experimental animals (142). Parida S et al. (141) found that commensal dysbiosis influenced the frequencies and numbers of macrophages during early or advanced stages of mammary tumor progression. Macrophages are one of the most abundant cell types within the breast tumor-microenvironment (143) and are a significant prognostic indicator of reduced survival for patients diagnosed with HR+ breast cancer (144). They observed that the majority of myeloid infiltrates within the mammary tumor microenvironment were M2-like macrophages during at early and advanced stages of tumor progression based upon CD206 expression. Importantly, the number of infiltrating tumor-promoting M2-like macrophages was significantly increased in advanced tumors of mice in the dysbiotic mice compared to non-dysbiotic controls with equal tumor burden. These data suggest that systemic expression of inflammatory mediators is increased in mice with dysbiosis tumors and that commensal dysbiosis acts synergistically with developing tumors to enhance myeloid recruitment into mammary tumors. Enhanced interstitial density or dense breast tissue is a recognized risk factor for the development of breast cancer metastases (145) and intra-mammary pro-tumor inflammation (146). They found that pre-established dysbiosis was associated with significantly enhanced collagen deposition in normal adjacent mammary glands and in tumors, and that collagen accumulation was slightly increased in the lungs of advanced tumor-bearing mice with dysbiosis, suggests that enhanced local and distal fibrosis is a long-term consequence of dysbiosis during breast cancer. Parida S et al. to determine whether gastrointestinal dysbiosis is sufficient to enhance mammary tumor cell dissemination (141), and a fecal microbiota transplantation (FMT) method was used, Both the experimental and control group and control groups were BRPKp110 breast tumor cells, Mice receiving flora-dysregulated cecal contents by FMT also showed enhanced infiltration of inflammatory myeloid cells into the mammary tissue and increased accumulation of myeloid cells into tumor tissue. Similar effects were observed in the mammary gland and tumor tissue during the advanced stages of tumor progression—that is, mammary gland tissue and tumors showed enhanced tissue fibrosis. Importantly, the spread of tumor cells to peripheral blood, lung, and distal axillary lymph nodes was also significantly increased in mice receiving dysbiosis flora (rather than “normal” FMT) by FMT, considering that a dynamically imbalanced microbiome is sufficient to enhance the metastatic spread of breast cancer. Moreover, it may be an independent correlate of the distant spread of tumor cells. Further supporting the idea that dysbiosis contributes to the evolution of breast tissue and/or tumors toward more aggressive and high-grade disease. regardless of the metastatic potential of the HR+ breast tumor model used in the study, dysbiosis of the gut flora was associated with enhanced dissemination and metastasis of breast tumor cells.

Changes in the gut microbiota also to effects in metabolites, and inflammatory signaling pathways can be amplified or inhibited. Using an in-situ mouse model of breast cancer, Kirkup et al. (147, 148) found significant differences in metabolic regulatory pathways across the tumor transcriptome in animals treated with broad-spectrum antibiotics, and single-cell transcriptomics revealed that the stromal cell population was altered in breast tumors from antibiotic-treated mice. The main form of the alteration was an increased number of mast cells, which accelerate tumor progression. The breast cancer model used a PyMT-derived ductal lumen cell line (PyMT-BO1) to investigate the role of gut microbiota in regulating the growth of primary mammary tumors (149). Disruption of intestinal microbiota by gavage administration of oral antibiotics (vancomycin, neomycin, metronidazole, amphotericin, and ampicillin [VNMAA]) prior to administration of tumor cells to animals, producing severe intestinal microbial changes (150, 151), and although no significant differences in tumor tissue structure were observed in those animals compared with a control group receiving plain water, significantly accelerated tumor growth was observed. Under a similar treatment regimen (152), enhanced growth resembling basal-like breast cancers was observed when spontaneously derived basal cells (EO771) were implanted in situ, suggesting that antibiotic-induced microbiota disruption can drive disease progression in multiple breast cancer subtypes. To determine the effect of the VNMAA mixture on the microbiota, microbial DNA was isolated from the cecum of control and VNMAA-treated animals on day 18 and subjected to birdshot macro-genomics analysis. The analysis revealed dramatic changes in the populations and overall diversity of the bacteria obtained from the animals that received VNMAA treatment, with the Shannon diversity index showing that the abundance of several microbial communities in the gut of antibiotic-treated mice was significantly reduced. In parallel, some communities (e.g., Fusobacterium nucleatum) persisted or overgrew. The composition of the gut microbiota was significantly altered in terms of species, abundance and overall diversity following the use of antibiotics, which was associated with accelerated tumor growth and an increase in mast cells in the tumor stroma. To determine whether mast cells affected tumor growth, Kirkup et al. (147) treated control and VNMAA-treated tumor-bearing mice with cromolyn (a mast cell stabilizer) and found that cromolyn inhibited tumor growth in the antibiotic-treated animals. Notably, the VNMAA-treated group without cromolyn treatment showed a significant increase in tumor size when compared to the control animals treated with cromolyn, and an increase in the number of mast cells was observed in sections of the EO771 tumor stroma taken from VNMAA-treated mice (147, 148). Those data suggessed the key role that mast cells play in tumor progression after antibiotic-induced microbiota disruption in mouse breast cancer: when vancomycin alone was used to induce microbiota disruption, effects similar to those already described were observed in a completely different model of breast cancer. Possibly, microbiota disruption was associated with increased homing of mast cells to, and/or increased proliferation within, tumor. However, given that mast cells in the control animals did not affect tumor progression, the pro-tumor function observed was shown to be specifically regulated by the microbiota. Given confirmation that antibiotic disruption of the gut microbiota has a detrimental effect on breast cancer, antibiotic-induced dysbiosis of the flora and dysregulation of the associated metabolites could be hypothesized to promote tumor growth by reprogramming mast cell homing and/or function. Future studies might consider determining the changes that occur in mast cells and breast tumor cells in response to gut dysbiosis. Kirkup et al. (147, 148) used a mixture of vancomycin, neomycin, metronidazole, and amphotericin (VNMA) to assess DNA concentrations in feces after microbiota dysbiosis and found very low DNA concentrations in the feces of the experimental group compared to the control group (water treatment). Importantly, the rate of PyMT-BO1 and EO771 breast tumor growth was significantly increased after disruption of the gut microbiota in the treated animals compared with the control animals (water treatment). Transcriptomic analysis also revealed dramatic differences in the regulation of metabolic pathways after antibiotic-induced dysbiosis of the intestinal flora, suggesting that accelerated breast cancer tumor growth might be associated with metabolic reprogramming. Fecal metabolomics was confirmed by 1H NMR spectroscopy analysis, which showed that 8 metabolites were elevated and 9 were significantly reduced in the major components of fecal samples from antibiotic-treated animals compared to fecal samples from control animals (147). Several of these amino acids (among them alanine, histidine and aspartic acid) were significantly increased in the antibiotic-treated animals. In contrast, the SCFAs butyrate and acetate, but not the branched-chain fatty acid isovalerate, were significantly reduced. Microbiota-derived butyrate is readily absorbed from the gut and can play a role in inhibiting histone deacetylases (153) in a variety of diseases, including cancer. Inhibition by butyrate can sensitize cancer cells to reactive oxygen species–induced apoptosis, thereby inhibiting the proliferation of breast cancer cells (154), but its role in the organism is yet to be confirmed in clinical trials. The authors hypothesized that a decrease in the bioavailability of the intestinal flora metabolite butyrate plays a role in enhanced tumor metabolism. Metabolites from the gut can reach distant tissues and organs such as the breast via the circulation, where they might play a role in regulating cancer cell function. Kirkup et al. noticed that antibiotics associated with breast cancer (e.g., cefadroxil, which is widely used in the USA after mastectomy). C57BL/6 mice carrying PyMT-BO1 tumor cells and receiving a cefadroxil dose equivalent to that in human patients experienced a significant acceleration in tumor growth. Analysis of the gut microbiota of the animals showed that the microbiota aggregates in samples from the experimental and control animals were independent and clustered differently before and after treatment. The relative abundance of Lactobacillus decreased over time in the control and experimental groups, and this appeared to be replaced mainly by fecal genera in the control animals, however, this did not occur in the antibiotic-treated animals. The genus with the most significant change in the microbial composition of the animals in the experimental group compared to the pre-treatment samples was Lactobacillus, but there was no significant difference before and after the control group. We presume that the disappearance of Lactobacillus might be driven by tumor cells, tumor–microbiota interactions, or natural maturation of the microbiome rather than by cefadroxil administration. Further analysis revealed differences in the abundance of 11 genera after cefadroxil treatment: Mucispirillum, Marvinbryantia, Parabacteroides, Anaeroplasma, Bacteroides, and Paraprevotella were significantly higher, and Alloprevotella, Alistipes, Odoribacter, Faecalibaculum, and Anaerotruncus were significantly lower. When multiple comparisons were made, 8 genera were significantly altered after antibiotic treatment. the genera that were significantly lesser abundant in treated animals relative to the controls, several are known butyrate-producing bacteria (e.g., Odoribacter and Anaerotruncus) or genera carrying the genes required for butyric acid production (e.g., Faecalibaculum and Alistipes) (147), consistent with the significant reduction in butyrate production observed in the metabolomic analysis of feces. That observation suggests that the use of a single antibiotic associated with breast cancer causes significant changes in microbiota genera and aggregation, potentially correlating with the tumor growth rate, but without a direct link to accelerated growth of breast tumors.

A major signaling route between the microbiome and the host is the secretion of Microbial metabolites that enter the circulation and reach their target cells (155–158). microbial metabolites synthesized in organs or glands (in this study, in the microbiome) function much like human hormones, in that they transfer to other anatomic locations and exert biologic effects (159). Microbial metabolites can enter the circulation and interfere with the steady-state of the intestinal and other local environments, acting as signaling mediators that influence the progression of breast cancer. SCFAs (160, 161), Lithocholic acid (LCA) (162–165), cadaverine (166), and de-conjugated estrogens (96, 109, 167), these metabolites have the ability to inhibit tumor-cell proliferation, the conversion of epithelial cells to mesenchymal cells, tumor metastasis, and cell migration and metastasis, and to induce antitumor immunity, to restructure cell metabolism, to induce senescence, and lower the number of tumor stem cells (164, 166, 168, 169).

The finding that perturbations in the gut microbiome are associated with tumor propagation at a distance supports the idea that the gut microbiome can be considered to be an endocrine gland (159, 170). Some metabolites associated with the activity of gut bacteria can enter the bloodstream and have been shown in vitro to affect the functioning of breast cancer and immune cells. Members of the microbiota can digest certain indigestible components of the human diet (e.g., dietary fiber), and SCFAs—for example, acetate, propionate, and butyrate—are components of metabolized dietary fiber (30, 171) and act as modulators of the host’s immune response. Bioactive compounds such as metabolic polyphenols (172) promote the growth of beneficial bacteria such as Bifidobacterium and Lactobacillus and produce SCFAs (173, 174). Some studies have shown that microbially derived homologous receptors for SCFAs were associated with a reduction in the invasive potential of breast cancer cells, with the homologous receptor FFAR2 inhibiting the Hippo-Yap pathway and increasing the expression of the adhesion protein E-cadherin, and FFAR3 inhibiting MAPK signalling (175), particularly butyrate, which has anticancer effects, as demonstrated in cancer cell cultures (176, 177) and animal models (160). Crucially, those microbial metabolites are produced after fermentation and/or metabolism of dietary components, and one of the key roles of the microbiota is to break down complex foods into simple bioactive compounds.

In the gut, disruption of the microbiota breaches the biologic barrier between it and the underlying tissue, leading to adverse physical contact between microbes and host cells, inducing paracrine production of bacterial metabolites (135). Changes in the microbiome have been associated with metabolic diseases such as obesity and type II diabetes (178), which are risk factors for certain cancers, including breast cancer (80, 179). The intestinal flora is responsible for the conversion of primary bile acids to secondary bile acids (180), and changes in the intestinal microbiota can therefore directly affect changes in secondary bile acids. Edit Mikóah et al. (169) studied three secondary bile acids—LCA, deoxycholic acid, and ursodeoxycholic acid. Of those three, LCA was found to exert a tumor-suppressive effect by reducing the growth of MCF7, SKBR3, and 4T1 breast cancer cells. They tested the cytostatic properties of LCA in mice transplanted with 4T1 breast cancer cells and found that the ability of the primary tumor to infiltrate surrounding tissues and metastasize was significantly reduced after LCA treatment. This study was the first to provide evidence for a mechanism of interaction between the microbiome and breast cancer by describing that LCA, a metabolite of microorganisms in the gut, is transferred to the breast via the bloodstream and might play an important role in promoting antiproliferative effects in breast cancer. However, LCA might be produced by the breast’s own microbiota and not only by the gut microbiota. The ratio of those two sources (breast and gut) in terms of LCA abundance is unknown and requires substantial research and continued trials.

Cadaverine is produced through lysine decarboxylation by lysine decarboxylase (181). Shigella felis, Shigella sonnei, Escherichia coli, and Streptococcus are all capable of expressing it (182). Kovács et al. (166) explored the effects of cadaverine supplementation (500 nmol/kg) on mice homozygously transplanted with 4T1 breast cancer cells and found a reduction in the aggressiveness of the primary tumor. Histologic examination of the primary tumors after cadaverine treatment showed a reduced mitotic rate and heterogeneity of nuclear morphology in the mammary tumor cells. To assess whether cadaverine treatment could convert mesenchymal-like carcinoma cells into epithelial-like cells, increased cadaverine resistance was measured using ECIS (Electric Cell-substrate Impedance Sensing), which showed better cell adhesion. To verify that finding, cells stained with Texas Red-X phalloidin and observed under microscopy showed that, after cadaverine treatment, the fibroblast-like morphology of 4T1, MDA-MB-231 and SKBR-3 breast cancer cells had changed to a cobblestone-like morphology that is characteristic of epithelial cells, and the inhibition of matrix metalloproteinase 9 expression also confirms the decrease in tumour cell migratory properties. A cellular flux analyser assessed the metabolic changes induced by necrotropism and found a reduction in glycolytic flux, which is characteristic of breast cancer mesenchymal cells (183). Cadaverine exerts its anticancer effects by inhibiting epithelial–mesenchymal transition, cell motility, chemotaxis, and metastasis. A further assessment of the “stemness” of 4T1 cells using an aldehyde dehydrogenase assay found that “stemness” was also slightly reduced (166). Dysbiosis of the intestinal flora (i.e., a change in the basal environment) leads to a change in the level and type of metabolites produced, which might have no effect on reducing the proportion of stem cells in breast cancer and slowing the rate of metastasis or might have the opposite effect, promoting malignant progression of the tumor. In the early stages of breast cancer in dysbiosis mice, bacterial cadaverine biosynthesis in the gut is reduced, leading to lower production of anti-cancer bacterial metabolites. We can speculate that in the presence of disturbed or slightly disturbed gastrointestinal flora, the metabolites produced act as signaling mediators and a specific crosstalk reaction may occur with the host, and this process may be directly or indirectly linked to the metastasis, migration and invasion of mammary tumors in mice.

A few studies have found that probiotic preparations are gaining in popularity for the improvement of health conditions such as antibiotic-induced diarrhea, irritable bowel syndrome, and obesity (184, 185). The use of probiotics can reduce or inhibit tumor growth, reduce tumor angiogenesis, tumor cell extravasation and lung metastasis (186). Long-term disturbance of the gut microbiome, which disrupts the probiotic structure and composition, may conversely increase the risk of breast cancer metastasis (187, 188).

Lactobacillus casei, a type of probiotic, is a Gram-positive bacterium that is resistant to the body’s defense mechanisms. After entering the human body, L. casei can survive in large numbers in the intestinal tract and can play a role in regulating the balance of intestinal flora, promoting digestion and absorption, among other processes (189). It is highly effective in lowering blood pressure (190) and cholesterol (191), promoting cell division and antibody immunity, enhancing human immunity, preventing cancer, and inhibiting tumor growth. Aragón et al. (186) used milk fermented with L. casei CRL431 to evaluate its possible effects on tumor growth, tumor cell extravasation and lung metastasis in a mouse model. By comparing mice fed fermented milk (FM), mice fed regular milk and mice not fed any special food, it was found that the group fed FM showed an inhibition of tumor growth and a decrease in tumor vascular filling, tumor cell extravasation and lung metastasis. Khoury et al. (192) used kefir water, a fermented milk product containing probiotics, to treat BALB/c mice that had been transplanted with 4T1 mammary cancer cells and, in the treated mice, detected a significant reduction in tumor size and weight, a significant enhancement of helper T cells and cytotoxic T cells, a significant reduction in lung and bone marrow metastases. Zamberi et al. (193) found that kefir water (mix of Lactobacillus acidophilus, Lactobacillus casei, and Lactococcus lactis) exerted an anti- angiogenic effect on mouse mammary tumors by down-regulating the tumor-promoting invasive interleukin 1β and vascular endothelial growth factor (a key mediator of angiogenesis). In the above model, levels of the pro-angiogenic factor interleukin 6 were found to have declined (186, 189, 194, 195) after probiotic treatment, suggesting that downregulation by Lactobacillus might affect the metastatic potential of cancer cells. some study (186, 196, 197) demonstrated that milk fermented with Lactobacillus casei CRL431 (probiotic fermented milk (PFM)) reduced the side effects of capecitabine and reduced intestinal mucositis and mortality in a mouse model of breast cancer by modulating the immune response, this suggests the potential of PFM as a probiotic as an immune adjuvant that may reduce tumor growth and metastasis without compromising the anti-tumor/anti-metastatic effects of chemotherapy. They differentially regulate cancer-related signaling pathways in a cell-type-specific manner and play a suppressive role in the pro-tumor microenvironment (198–200). Conversely, disruptions in the intestinal flora might simultaneously or subsequently affect the probiotic environment, which could cause probiotics to lose their “dominant” role in the tumor environment, negatively affecting the control or inhibition of breast tumor cell growth or even accelerating the growth of tumor cells and promoting angiogenesis, becoming an indirect contributor to tumor metastasis. Yazdi et al. (201) demonstrated that selenium-nanoparticle-enriched L. brevis administered to mammary tumor-bearing BALB/c mice induced an effective immune response, resulting in reduced liver metastases and an increased lifespan, included increases in the T helper cytokines, interferon-gamma and interleukin 17, and enhanced natural killer cell activity. Hassan Z et al. Demonstrated that (202) Enterococcus faecalis and Staphylococcus hominis can significantly inhibit cell proliferation, induce apoptosis, and cell cycle arrest, and that they have no cytotoxic effect on normal cells, making them a good alternative drug for breast cancer treatment ( Figure 1 ).

Figure 1 . The linkage between probiotic environmental homeostasis and breast cancer metastasis

Probiotics have specific anticancer properties, and studies have shown that they can alter the expression of various genes involved in apoptosis (203), invasion and metastasis (204), maintenance of cancer stem cells (205), and control of the cell cycle (206). Probiotics have been highlighted as superior in the treatment of cancer. however, more pre-clinical and clinical studies are needed to determine which strains are beneficial during specific treatments before probiotic administration is considered safe and customisable for all individuals.

Although the correlations between BRCA risk and dietary intake have been intensively studied, the underlying associations or effector mechanisms remain poorly understood. Historically, increased risk of BRCA has been tied to high intake of red meat and animal fat (207, 208), with decreased risk being concurrently linked to fruit and vegetables consumption (209). Changing dietary patterns affects the microbiome and Indirect affects the development of breast cancer. A case-control study in Japan showed that regular consumption of Lactobacillus casei Shirota and soy isoflavones from puberty onwards reduced the incidence of breast cancer in Japanese women (210); Newman TM et al. also indicated that the Mediterranean diet could prevent breast cancer, because of its inclusion of an abundance of plant-based foods and the lack of processed foods (211). Xue M et al. confirmed through experiments (212) that fucoidan increases the diversity of intestinal flora and can promote the intestinal barrier function, and he suggested fucoidan as a preventive agent for breast cancer. studies have shown that increased polyphenol intake is associated with higher levels of beneficial bacteria (such as Bifidobacterium and Lactobacillus) and SCFAs in humans (174), while also decreasing levels of bacteria that have been associated with disease, so‐called pathobionts. Diet is an important factor in all microbiota studies and can help maintain the stability of gut microbes, which can influence the development of breast cancer. If dietary interventions are to be successfully used in future treatments, studies of diet and microbiota metabolites might have to be conducted in parallel. Indeed, recent studies have highlighted the personalised response to individuals (and the microbiota) to the same diet (213), which highlights the limitations and challenges for next‐stage studies of this kind.

Alcohol consumption increases the risk of breast cancer, although alcohol itself is not a direct carcinogen, acetaldehyde, a product of alcohol metabolism, is a mutagen which can form adducts with protein and DNA, inducing gene mutation, DNA crosslinks and chromosomal aberrations (214–216). Many studies have also confirmed that alcohol consumption not only induces breast cancer development (217, 218) but also promotes the progression of existing breast tumors and induces a more aggressive phenotype (219–222). There are no clear reports to confirm the correlation between alcohol, microorganisms and breast cancer metastasis, but there is no doubt that alcohol causes dysbiosis of the intestinal flora (223–225). It is not difficult to guess that there may be an alcohol-gut flora-breast cancer axis, which means that changing lifestyle habits could have profound implications for the prevention and prognosis of the disease, but the role of gut flora in this needs to be studied in depth.

Details of the following studies included in this review are summarized in Table 3 .